Patrick C. Thornton

Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver.

SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver.

Journal: European journal of haematology

Published: June 30, 2026

Maternal and neonatal outcomes in pregnant patients with Brugada Syndrome - a multicentre retrospective study (2014-2025).

Maternal and neonatal outcomes in pregnant patients with Brugada Syndrome - a multicentre retrospective study (2014-2025).

Journal: International journal of obstetric anesthesia

Published: March 18, 2026

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 17, 2026

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Journal: Blood

Published: February 24, 2025

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 10, 2024

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: May 10, 2023

Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.

Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.

Journal: International journal of hematology

Published: March 06, 2023

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

Journal: Blood

Published: January 17, 2023

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Journal: Leukemia

Published: January 12, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026